Oftaquix (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cells from multiplying, leading to bacterial death and clearance of the infection in the eye.

The dosing regimen for Oftaquix is determined by the prescribing clinician based on the severity of the infection, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration appropriate for each individual case.

Levofloxacin is generally reserved for use in pregnancy or lactation only when the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit profile before prescribing this medication to pregnant or nursing women.

To request Oftaquix, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oftaquix (levofloxacin) belongs to the fluoroquinolone class, offering broad‑spectrum activity against Gram‑negative and Gram‑positive ocular pathogens. Compared with older agents such as ciprofloxacin, levofloxacin often provides enhanced potency and a lower dosing frequency, while maintaining a similar safety profile.

Oftaquix should be stored at room temperature, protected from light and moisture. Keep the vial in its original packaging and ensure the cap is tightly closed when not in use. Do not freeze the solution, and discard any product that appears discolored or contaminated.

The medication is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and instill the prescribed number of drops. The eye should be closed gently for a few seconds to allow absorption, avoiding blinking or rubbing.

Serious risks, though rare, include severe allergic reactions, Stevens‑Johnson syndrome, corneal ulceration, and vision loss. Patients should seek immediate medical attention if they experience swelling, rash, worsening eye pain, or any sudden change in vision after using the drops.

Individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation should avoid using Oftaquix. Caution is also advised for patients with a history of tendon disorders or those taking systemic fluoroquinolones, unless directed by a healthcare professional.